Safety, Tolerance and Activity of HE3286 in Patients With Type 2 Diabetes Mellitus

Completed · Phase 2 · Has a placebo group

Conditions studied: Type 2 Diabetes Mellitus

In brief

This is a phase II, double-blind, randomized, placebo-controlled study of the safety, tolerance and activity of HE3286 in patients with type 2 diabetes mellitus. Patients receiving stable metformin or who are drug-naive will receive study treatment (HE3286 or placebo) for a treatment period of 12-weeks.

Key facts

Study ID

NCT00694057

Run by

Harbor Therapeutics

People needed

164

Starts

2008-06-01

Expected to finish

2010-01-01

Last updated by the study team

2011-06-14

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Study site — Anaheim, California, United States
• Study site — Anaheim, California, United States
• Study site — Beverly Hills, California, United States
• Study site — Buena Park, California, United States
• Study site — Burbank, California, United States
• Study site — Carmichael, California, United States
• Study site — Escondido, California, United States
• Study site — Fresno, California, United States
• Study site — Huntington Park, California, United States
• Study site — Long Beach, California, United States
• Study site — Los Angeles, California, United States
• Study site — National City, California, United States
• Study site — Roseville, California, United States
• Study site — Chicago, Illinois, United States
• Study site — Baton Rouge, Louisiana, United States
• Study site — St Louis, Missouri, United States
• Study site — Las Vegas, Nevada, United States
• Study site — Las Vegas, Nevada, United States
• Study site — El Paso, Texas, United States
• Study site — San Antonio, Texas, United States
• Study site — Salt Lake City, Utah, United States
• Study site — Kenosha, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.